Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NSUN5 is a highly conserved rRNA methyltransferase that catalyzes the methylation of cytosine 3782 in human 28S rRNA (and homologous sites in other species), regulating ribosome structure and global protein synthesis[1][2][3]. Its functional activity depends on conserved cysteine residues essential for catalysis and RNA binding/release[3][4]. NSUN5 localizes to nucleoli, where rRNA is transcribed and processed[3]. Loss or mutation of NSUN5 reduces rRNA methylation, impairs global protein translation but not ribosome biogenesis or translational fidelity, and is associated with cell growth defects[3]. It has disease relevance in cancer (e.g., glioma, colorectal cancer) where its expression promotes cell proliferation, and in Williams-Beuren syndrome where its deletion is linked to neurodevelopmental phenotypes[2][4]. NSUN5's newly emergent role also includes modulation of immune evasion pathways in glioma, adding therapeutic interest[4].
Drugs targeting NSUN5 would theoretically act by inhibiting rRNA methylation, suppressing ribosome function, and reducing translation, with implications for cancer proliferation and immune modulation[2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 28S rRNA cytosine-C(5) methyltransferase (NSUN5) (NSUN5).